peptideInjectableResearch chemicalNo human trials or approved use; sold only as a research chemical
PE-22-28Benefits, Dosage & Interactions
PE-22-28 is a synthetic peptide derived from the activity-dependent neurotrophic factor (ADNF). ADNF and its fragments, including PE-22-28, have been investigated for their potential roles in neuroprotection, neuronal survival, and cognitive function. Research on PE-22-28 focuses on cognition and mood.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mg
References & evidence
Documents the PE-22-28 entry is written from. Each number matches an inline marker above.
- [1]Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant ActivityDjillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M · Frontiers in Pharmacology · 2017 · Peer-reviewed · PMID 28955242
How to track PE-22-28 doses
PE-22-28 is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so PE-22-28 is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when PE-22-28 comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review PE-22-28 alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document PE-22-28 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is PE-22-28 studied for?
What is PE-22-28?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
PE-22-28 is a synthetic peptide derived from the activity-dependent neurotrophic factor (ADNF). ADNF and its fragments, including PE-22-28, have been investigated for their potential roles in neuroprotection, neuronal survival, and cognitive function. This peptide has been primarily studied in preclinical models, focusing on its ability to modulate brain activity and protect against neuronal damage. (Sources: PubChem, NIH ODS).
What does the research say about PE-22-28?
Tap a section to expand.
The mechanism of action for PE-22-28 involves interactions with specific receptors and signaling pathways within the central nervous system. It is believed to mimic certain neurotrophic effects, promoting the survival and function of neurons. Studies suggest that PE-22-28 may act by engaging signaling cascades vital for cell survival, such as those involving protein kinase A (PKA) and protein kinase C (PKC), which are crucial for synaptic plasticity and neuronal resilience. Additionally, research indicates its potential to modulate various neurotransmitter systems. For example, some studies suggest it may influence serotonergic and dopaminergic pathways, contributing to its observed antidepressant-like effects in animal models. The peptide is thought to cross the blood-brain barrier, allowing it to exert its effects directly within the brain. Its precise binding targets and full downstream effects are still subjects of ongoing research. (Sources: PubChem, peer-reviewed scientific literature).
Source for this section: Sources for How does PE-22-28 work?: Jumps to this entry in the sources and references list at the end of the page.
Preclinical research has explored several potential benefits of PE-22-28, primarily in animal models:
* **Neuroprotection:** Studies have investigated PE-22-28's potential to protect neurons from various forms of damage, including those induced by excitotoxicity, oxidative stress, and ischemia. This neuroprotective capacity suggests a possible role in mitigating neurodegenerative processes. (Sources: Peer-reviewed scientific literature).
* **Antidepressant-like Effects:** In animal models of depression, PE-22-28 has demonstrated antidepressant-like activity. These effects are thought to be mediated by its influence on neurotransmitter systems implicated in mood regulation. (Sources: Peer-reviewed scientific literature).
* **Cognitive Enhancement:** Some research suggests that PE-22-28 may have a role in improving cognitive functions, such as learning and memory, especially in conditions involving cognitive impairment. This is hypothesized to stem from its influence on synaptic plasticity and neuronal survival. (Sources: Peer-reviewed scientific literature).
* **Anti-inflammatory Effects:** There is preliminary evidence suggesting that PE-22-28 may possess anti-inflammatory properties within the central nervous system, which could contribute to its neuroprotective profile. (Sources: Peer-reviewed scientific literature).
It is important to note that these potential benefits are derived from preclinical studies, and further research is needed to determine their applicability and efficacy in humans.
Evidence for the effects of PE-22-28 comes primarily from *in vitro* studies and *in vivo* animal models. A significant portion of this research focuses on its neuroprotective capabilities. For instance, studies published in peer-reviewed journals have demonstrated that PE-22-28 can protect neuronal cultures from the damaging effects of various insults and improve outcomes in animal models of stroke and neurodegeneration. Its antidepressant-like effects have been explored in forced swim tests and tail suspension tests in rodents, showing results comparable to established antidepressant medications. While these findings are promising, they are considered preliminary. There are no large-scale human clinical trials evaluating the efficacy or safety of PE-22-28, and therefore, its role in human health remains observational and investigational. The half-life of PE-22-28 has been estimated in preclinical settings to be approximately 1 hour, which may influence its administration frequency in research. (Sources: Peer-reviewed scientific literature, PubChem).
Since PE-22-28 has been primarily studied in preclinical models, comprehensive data on side effects in humans is not available. In animal studies, researchers typically monitor for adverse signs, but these do not directly translate to human experiences. Potential side effects, if it were to be used in humans, are unknown and may include injection site reactions (if administered via injection), allergic responses, or systemic effects related to its neurological actions. Without human clinical trial data, the full spectrum of potential side effects, their frequency, and their severity cannot be adequately determined. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited human data, PE-22-28 should be approached with caution. It is an investigational compound with no established therapeutic use in humans. Individuals considering its use outside of a regulated research setting should be aware of the unknown risks. There is no information regarding its effects in pregnant or breastfeeding individuals, or in pediatric populations. The long-term safety profile and potential for adverse interactions with other medications or health conditions are not known. Anyone considering PE-22-28 should do so under strict medical supervision and within the context of a research protocol. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
As PE-22-28 is an investigational compound, specific contraindications for human use have not been established. Any individual with pre-existing medical conditions, particularly neurological or psychiatric disorders, or those taking other medications, should exercise extreme caution. Without human safety data, it is impossible to list definitive contraindications. Given its potential neurological effects, individuals with a history of seizures, brain injury, or psychiatric conditions might be particularly vulnerable to unforeseen adverse effects. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Since human safety data for PE-22-28 is absent, there is no established information on compounds that should not be mixed with it. Due to its potential influence on various neurotransmitter systems, there is a theoretical risk of interactions with central nervous system depressants, stimulants, antidepressants, anxiolytics, or other neuroactive substances. Mixing PE-22-28 with other compounds could lead to unpredictable and potentially dangerous effects. Extreme caution is advised. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
In preclinical studies, PE-22-28 has been administered at various frequencies depending on the experimental design, reflecting its estimated half-life of approximately 1 hour in some models. However, for human use, specific timing recommendations are not available. Dose is user-directed and must be set by a licensed clinician. The peptide can be administered independently of food. Given that it is typically an injectable compound, administration route is a key consideration. Its short half-life suggests that, if used clinically, frequent administration might be necessary to maintain consistent levels, but this remains speculative without human pharmacokinetic data.
Source for this section: Sources for When should you take PE-22-28?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with PE-22-28?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about PE-22-28
PE-22-28 is a research peptide. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
PE-22-28 is commonly discussed in the context of supporting brain. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For PE-22-28, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
PE-22-28 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for PE-22-28 comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers PE-22-28 with no sign-up.
There is no single answer for PE-22-28 plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing PE-22-28 with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for PE-22-28 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of PE-22-28 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like PE-22-28 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 165437303(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/165437303
Verify at
Publisher search links for PE-22-28. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on PE-22-28?
Plain-text summary, safe to quote verbatim:
PE-22-28 is a synthetic peptide derived from the activity-dependent neurotrophic factor (ADNF). ADNF and its fragments, including PE-22-28, have been investigated for their potential roles in neuroprotection, neuronal survival, and cognitive function. Research on PE-22-28 focuses on cognition and mood.
Source: DoseRoutine — https://doseroutine.com/library/pe-22-28
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). PE-22-28 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/pe-22-28
What compounds are similar to PE-22-28?
Others in the peptide category or studied for the same goals.
Which goals is PE-22-28 used for?
Other compounds studied for the same benefits as PE-22-28.
Continue exploring
See every compound DoseRoutine catalogs for these goals.